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942Detection of High-Risk Atherosclerotic Plaque
Report of the NHLBIWorkingGroup on Current Status and Future Directions
The leading cause of major morbidity and mortality in most countries around the world is atherosclerotic cardiovascular
disease, most commonly caused by thrombotic occlusion of a high-risk coronary plaque resulting in myocardial infarction or
cardiac death, or embolization from a high-risk carotid plaque resulting in stroke. The lesions prone to result in such clinical
events are termed vulnerable or high-risk plaques, and their identification may lead to the development of pharmacological
nd mechanical intervention strategies to prevent such events. Autopsy studies from patients dying of acute myocardial
nfarction or sudden death have shown that such events typically arise from specific types of atherosclerotic plaques, most
ommonly the thin-cap fibroatheroma. However, the search in human beings for vulnerable plaques before their becoming
ymptomatic has been elusive. Recently, the PROSPECT (Providing Regional Observations to Study Predictors of Events in the
oronary Tree) study demonstrated that coronary plaques that are likely to cause future cardiac events, regardless of
ngiographic severity, are characterized by large plaque burden and small lumen area and/or are thin-cap fibroatheromas
erifiedby radiofrequency intravascular ultrasound imaging. This studyopened thedoor to identifyingadditional invasive and
oninvasive imaging modalities that may improve detection of high-risk atherosclerotic lesions and patients. Beyond classic
isk factors, novel biomarkers and genetic profiling may identify those patients in whom noninvasive imaging for vulnerable
laque screening, followed by invasive imaging for risk confirmation is warranted, and in whom future pharmacological
nd/or device-based focal or regional therapies may be applied to improve long-term prognosis. (J Am Coll Cardiol Img
012;5:941–55) © 2012 by the American College of Cardiology FoundationS
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he National Heart, Lung, and Blood Institute
(NHLBI) convened a Working Group in Be-
thesda, Maryland, on June 8, 2009, to examine
the current state of the art in the identification of
igh-risk atherosclerotic plaque and provide recom-
endations for future research. After discussing the
ROSPECT (Providing Regional Observations to
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8, 2012, accepted July 19, 2012.tudy Predictors of Events in the Coronary Tree)
tudy (1) and related natural history studies, we review
he pathological basis for high-risk plaques, invasive
nd noninvasive plaque imaging modalities, biomark-
rs that may help to identify high-risk patients, and
nimal models of coronary atherosclerosis, and con-
lude with the identification of future research prior-
ties and recommendations.
The Nature and Natural History of Vulnerable
Plaque: a Convergence of Understanding
Vulnerable plaque is a term that represents “the
susceptibility of a plaque to rupture” (2). From
autopsy studies in patients who had died of cardiac
causes, the most common underlying plaque mor-
phology was a ruptured thin-cap fibroatheroma
(TCFA), with superimposed thrombosis (3). Given
this pathophysiological background, the goal
emerged to identify such vulnerable plaques in
stable patients, with the ultimate goal of preventing
plaque rupture, thereby averting myocardial infarc-
tion (MI) and sudden cardiac death. It was origi-
nally believed that most cases of acute coronary
syndrome (ACS) would arise from acute coronary
occlusion by severe atherosclerotic plaques. Early
prospective angiographic studies, such as the ran-
domized CASS (Coronary Artery Surgery Study) of
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943medical therapy versus coronary artery bypass graft
surgery, seemed to support this hypothesis, demon-
strating that severely stenotic angiographic lesions
were more likely to result in future coronary occlu-
sion and MI than milder stenoses (4). In contrast,
retrospective studies reported that the lesions most
likely to cause future MI arise from angiographi-
cally mild lesions (5). Similarly, a study from the
1997 to 1999 NHLBI Dynamic Registry reported
that in 5.8% of 3,747 patients undergoing percuta-
neous coronary intervention (PCI), clinical progres-
sion of coronary artery disease (CAD) (most often
ACS) developed within 1 year, requiring an un-
planned revascularization procedure. In these pa-
tients, the mean angiographic diameter stenosis
progressed from 42  21% to 84  14% in a mean
of 5.2 months (6). A major limitation of these
studies was the reliance on coronary angiography to
determine lesion severity and plaque composition.
In contrast to angiography, gray-scale intravascular
ultrasound (IVUS) imaging, based on amplitude anal-
ysis of sound waves backscattered from tissue, can
visualize the external elastic lamina of the vessel wall,
allowing determination of vessel size and plaque bur-
den and morphology (7). Radiofrequency (RF) anal-
ysis of the ultrasonic signal (virtual histology RF-
IVUS) permits further characterization of plaque
composition, which correlates well with histological
analysis (8). With RF-IVUS, coronary atherosclerotic
lesions can be classified into TCFA, thick-cap fibro-
atheromas, pathological intimal thickening, fibrotic
plaque, and fibrocalcific plaque.
In the prospective, multicenter PROSPECT
study of patients presenting with ACS, 3-vessel
angiography and intracoronary imaging with gray-
scale and RF-IVUS were performed to evaluate the
characteristics of nonculprit lesions that progress over
time to result in major adverse cardiac events
(MACE), defined as the composite of cardiac death,
cardiac arrest, MI, or unstable/increasing angina re-
quiring rehospitalization (1). In PROSPECT, 697
patients (median age, 58 years; 76% men, 17% with
diabetes) presenting with ACS (30% ST-segment
elevation MI, 66% non–ST-segment MI, 4% un-
stable angina) underwent uneventful 1- or 2-vessel
PCI followed by quantitative angiography of each
millimeter of the entire coronary tree with a diam-
eter 1.5 mm. In addition, the proximal 6 to 8 cm
of all 3 major coronary arteries were imaged using
RF-IVUS. By angiography, 1,814 untreated lesions
(i.e., those with a visually estimated diameter ste-
nosis of 30%) were prospectively identified in the
entire coronary tree, and 3,160 untreated lesions swere identified by IVUS, defined as 3 consecutive
frames with plaque burden 40% (7).
Patients were followed prospectively to deter-
mine which patient and lesion characteristics would
correlate with future events. By 3 years, a new
MACE had occurred in 20.4% of patients, nearly
equally divided between those caused by untreated
nonculprit lesions and those arising from the orig-
inal ACS culprit lesions that were previously treated
by PCI (Fig. 1, top). Most lesions causing noncul-
prit lesion events arose from angiographically mild
(50%) stenoses; the mean angiographic
diameter stenosis of the 106 nonculprit
lesions subsequently responsible for MACE
increased from 32.3  20.6% at baseline to
65.4 6.3% at follow-up (p 0.001), often
with new plaque rupture and/or thrombus.
However, likely due to intensive pharmaco-
therapy and close follow-up, most patients
presented with severe progressive or unstable
angina, not death or MI, and were effectively
treated by revascularization, usually PCI (1).
By multivariable analysis, the only clin-
cal variables independently associated
ith nonculprit lesion MACE during
ollow-up were insulin-treated diabetes
nd previous PCI (1). No angiographic
ariable was strongly associated with sub-
equent events. However, significant inde-
endent predictors of nonculprit lesion-
elated MACE (i.e., events arising from
hose specific untreated lesions) were
laque burden 70% (hazard ratio [HR]:
.03; p  0.001), the presence of a TCFA
by RF-IVUS (HR: 3.35; p  0.001), and
minimal lumen area 4.0 mm2 (HR:
.21, p 0.001). The presence of 2 or 3 of
hese 3 characteristics identified lesions with
10% and 18% likelihood, respectively, of
n event arising from that site within 3
ears (1). Conversely, the 3-year noncul-
rit lesion–related MACE rate in 1,650
VUS lesions with none of these 3 char-
cteristics was only 0.3% (Fig. 1, bottom), and no
vents arose from coronary segments with 40%
laque area.
This prospective study therefore demonstrated that
he plaques likely to cause future coronary events are
ndeed typically severe, either with a large plaque
urden and/or a small minimal lumen area (1). The in
ivo observation from the PROSPECT study that
CFA identified by RF-IVUS represent the plaque
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944also confirms the findings from post-mortem patho-
logical studies and validates the utility of RF-IVUS as
an imaging tool capable of identifying vulnerable
plaques before they cause subsequent MACE (9).
Pathological Basis for Imaging Vulnerable Plaques
Pathological intimal thickening is the first and most
common clinically detectable manifestation of ath-
erosclerosis in humans (10). Unique to these lesions
is the presence of lipid pools located in the deeper
intima in areas rich in proteoglycans with speckled
calcification and a generalized loss of smooth mus-
cle cells. The loss of these cells in lipid pools occurs
from cell death, including apoptosis, characterized
by prominent basal laminae around clusters of
vesicles, consistent with a smooth muscle cell origin
(11). The extent of macrophage infiltration is vari-
ll Events
20.4
Culprit Lesion
Events
12.9
Non Culprit
Lesion Events
11.6
Indeterminate
Events
2.7
umber of High-risk Features Present in Each Lesion
Zero
5/1650
0.3
One
46/1059
4.8
Two
24/253
10.5
Three
5/29
18.2
ory of Coronary Artery Lesions in ACS: The PROSPECT Study
f treated and untreated coronary artery lesions in patients with
mes. Incidence of major adverse cardiac events (MACE) (cardiac
yocardial infarction, or rehospitalization due to unstable or pro-
ears after successful percutaneous coronary intervention (PCI) for
me in 697 patients from the PROSPECT study. Among the 20.4%
g events, lesions originally treated by PCI (culprit lesions) and
lesions accounted for nearly equal numbers of events. A small
ere of indeterminate lesion origin because coronary angiography
the time of the event. (Bottom) The rate of MACE per lesion dur-
of 3.4 years according to the number of high-risk PROSPECT
t baseline. The high-risk characteristics are a plaque burden
n area 4.0 mm2, and a thin-cap ﬁbroatheroma as assessed by
ascular ultrasound. The fraction below the x-axis is the number of
each combination of events (denominator) and the number of
lted in a MACE event during follow-up (numerator). Adapted, with
et al. (1).able and mostly confined to the luminal aspect ofthe plaque outside the lipid pool. The development
of advanced atheromatous plaques with necrotic
cores is believed to occur due to invasion of lipid
pools by macrophages. Figure 2 demonstrates sev-
eral important pathological features of atheroscle-
rotic coronary plaques.
Autopsy studies have shown that a ruptured
TCFA with overlying thrombus is the most com-
mon plaque morphology in the coronary arteries of
patients dying of acute MI or sudden cardiac death
(3). Thus, the ability of imaging techniques to
detect intact TCFA before rupture depends on their
ability to detect the typical morphological and
biological/functional characteristics of these lesions.
By definition, a TCFA contains a large necrotic
core of lipid and cellular debris, covered by a thin
fibrous cap, usually 65 m in thickness. The
fibrous cap is heavily infiltrated by inflammatory
cells and macrophages, indicating the important
role of inflammation in plaque instability. Spotty
calcifications are often present in the fibrous cap.
Neovascularization of the arterial wall, caused by
the proliferation of adventitial vasa vasorum in
response to hypoxia-induced thickening of the ar-
terial wall, may result in intraplaque hemorrhage.
Expansive remodeling of the arterial wall occurs,
presumably due to the large plaque burden and
limited room for inward growth.
Considering that the necrotic core is a recognized
feature of plaque vulnerability, it is particularly
important to understand the role of primary and
secondary inflammation, cell death, and removal of
debris, and other crucial factors that may be in-
volved in the formation of the necrotic core, such as
tissue disruption proteases (12) and hemorrhage
(13). The free cholesterol content of necrotic cores
in high-risk plaques is markedly greater than in
lower-risk plaques. Free cholesterol is prominently
deposited by the extravasation of erythrocytes from
the intimal neovascularization; the new vessels are
leaky, and red blood cell membranes are rich in free
cholesterol (13). The vulnerable plaque is typically
proximal in location, except in the right coronary
artery, and more likely to occur near branch points
because its occurrence is directed by biomechanical
flow disturbances (14). Because only a fraction of
vulnerable plaques will likely progress to rupture,
and of those that rupture, only a minority will cause a
clinical event, the challenge is to identify the unique
features critical to this outcome. Various noninvasive
imaging techniques may serve as useful screening tools
to help identify vulnerable patients and elucidateM
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945However, it is likely that confirmation of coronary
plaque vulnerability will require intravascular imaging
procedures, given their close proximity to the plaque
with a higher attendant signal-to-noise ratio, allowing
better definition of morphological features associated
with future plaque rupture (15).
Intracoronary Imaging Strategies for
Confirmation of Plaque Characteristics
IVUS: plaque burden, lipid ﬁbrous content, and
remodeling. Although IVUS has been widely used
to examine the coronary arterial tree, several recently
developed applications of IVUS have helped to detect
unstable plaques, including backscatter RF analysis for
tissue characterization, elastography, shear stress map-
ping, vasa vasorum imaging, thermal strain imaging,
and measurement of transverse stress tensor (Fig. 3)
(16). Some applications such as RF analysis provide
information regarding plaque composition, whereas
other applications provide functional or physiological
data that could be used for mechanistic studies of
disease progression. RF ultrasound signals allow iden-
tification of different components of atherosclerotic
plaques: calcium, fibrous tissue, fibrofatty tissue, and
necrotic core (8). Ex vivo validation studies have
reported high accuracy for the classification of those
plaque signatures. Clinical studies have shown the
applicability of RF analysis for characterization of
Figure 2. Representative Lesion Morphologies for Progressive H
(A) The earliest atherosclerotic lesion, pathological intimal thicken
chrome stain) with CD68 macrophages near the luminal surface.
lipid pool into a necrotic core; note the invasion of the lipid pool b
lytic environment and increase in size. (D) An advanced thin-cap ﬁb
necrotic core and thin ﬁbrous cap inﬁltrated by macrophages. NC 
Farb A, Gold HK, Finn AV, Kolodgie FD. Plaque rupture. In: Virmani
rotic Plaque: Strategies for Diagnosis and Management. Malden, MAcoronary lesions (1,17), as discussed earlier.Assessment of plaque instability may be en-
hanced by considering the combination of cap
thickness, necrotic core thickness (rather than
an Coronary Atherosclerosis
highlighted by lipid pools (LP) in the deep intima (Movat penta-
ibroatheroma with early necrosis, showing the conversion of a
acrophages. (C) A late core ﬁbroatheroma, distinguished by its
theroma (rupture-prone lesion), characterized by a relatively large
crotic core. Adapted, with permission, from Virmani R, Burke AP,
arula J, Leon M, Willerson J, editors. The Vulnerable Atheroscle-
ackwell Futura, 2007:37–59.
Figure 3. Various Intravascular Ultrasound Imaging Modalities
to Assess Coronary Plaques
(A) Plaque composition (virtual histology); courtesy of G. Finet.
(B) Palpography; reprinted with permission from Schaar et al. (21).
(C) Strain map (or elastogram); reprinted, with permission, from
Le Floc’h et al. (22). (D) Elasticity map (or modulogram); reprinted, with
permission, from Maurice et al. (20). The elastogram and modulogramum
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946global size), and the arterial remodeling index (18)
(Fig. 4). At the early stages of positive vascular
remodeling (PVR), lesions with large relative ne-
crotic cores are biomechanically more prone to
rupture, which could explain the progression and
growth of clinically silent plaques (18). Although
various IVUS methodologies (19 –21) provide
plaque composition and morphology, biomechani-
cal approaches have been employed to obtain in vivo
modulograms (Young’s modulus maps) of athero-
matous plaques (22) for quantification of stiffness
distribution across the plaque (Fig. 3D).
Angioscopy: plaque surface characteristics. Similar to
ltrasound, optical characterization of atheroscle-
otic plaques may provide information about lipid
omposition of high-risk plaques. Angioscopy has
onsistently demonstrated an association between
ellow plaque color and lipid-rich plaques, includ-
ng those causing MI (23,24). Angioscopy has also
stablished a link between the presence of yellow
laques and the risk of subsequent coronary events
24). Yellow plaques defined by quantitative color-
metry have been associated with lipid core plaques
LCP) underneath thin fibrous caps and high-risk
esions in patients. Furthermore, certain colorimet-
ic characteristics (including yellow and red colors)
ay be very sensitive and specific for lipid cores
nderneath thin fibrous caps. Angioscopy has also
dentified an association of yellow plaque with
elayed and incomplete healing and the presence of
hrombus within drug-eluting stents (25).
Near-infrared spectroscopy: lipid core burden. Ath-
rosclerotic plaques, especially lipid-rich plaques,
ave a specific chemical signature related to choles-
erol esters present in lipid cores. Ex vivo studies
ave demonstrated the feasibility of atherosclerotic
ipid-rich plaque detection using near-infrared
pectroscopy (NIRS). A catheter-based NIRS sys-
em and a chemometric algorithm for the detection
f LCP was recently developed and prospectively
alidated in a human coronary artery autopsy study
26). NIRS data are presented as a “chemogram”
epresenting the probability that an LCP is present
yellow for high probability, red for low probabil-
ty). LCP was defined as fibroatheroma with a lipid
ore 60° in circumferential extent and 200 m
in thickness on a cross-sectional histological speci-
men, with a fibrous cap with a mean thickness
450 m. NIRS identified localized LCP with an
rea under the receiver-operating characteristic
urve of 0.80 in vessels 3.0 mm in diameter. A
rst-in-human validation study demonstrated the
athematical and statistical similarity of spectracquired in vivo compared with those obtained in
utopsy specimens (Fig. 5) (27); the algorithm
dentified LCP in 60% of imaged segments in
atients undergoing PCI for stable angina or ACS.
IRS can collect data with rapid acquisition times,
voiding the need to obstruct blood flow. A limi-
ation of NIRS, however, is that it does not create
n image of the vessel wall. Thus, no information is
rovided on the depth of LCP. Fibroatheromas
hat are thick capped or too small to be defined as
CP are major sources of false-positive readings.
Optical coherence tomography: ﬁbrous cap thickness.
Optical coherence tomography (OCT), a technique
that measures the depth-resolved back-reflection of
infrared light, offers high-resolution measurement
of fibrous cap thickness, the most important char-
acteristic of high-risk plaque. Newer OCT systems
may also define the macrophage density (28) and
collagen composition of fibrous caps (29). OCT has
an axial (depth) resolution of 5 to 20 m and a
transverse resolution of 30 m, which are 10-fold
igher than those for IVUS. Imaging depth within
he coronary wall ranges from 1 to 3 mm, depending
Figure 4. Graph Highlighting the Inﬂuences of
Remodeling Index and Relative Necrotic Core Thickness on
Critical TCFA Thickness
The critical thin-cap ﬁbroatheroma (TCFA) thickness is deﬁned as
the value at which cap stress reaches the critical or rupture
point tensile stress. Vulnerable plaques with relative necrotic
core thicknesses of 90%, 70%, 50%, 30%, and 10% become
unstable below their respective curves. Thus, the unstable
region for vulnerable plaques with relative necrotic core thick-
ness of 10% is indicated in light gray, whereas for 30% thick-
ness, the unstable region is the summation of gray and green
light areas. Plaques with low remodeling index and a large rela-
tive necrotic core thickness are more prone to rupture, having a
higher critical TCFA thickness. Reprinted, with permission, from
Ohayon et al. (18).
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947on tissue type. The high resolution of OCT uniquely
enables the visualization of microstructural features of
coronary plaque types implicated in ACS.
Clinical applicability of OCT was initially lim-
ited by attenuation of its optical beam by intralu-
minal blood, which prevented clear visualization of
the vessel wall. Second-generation OCT technolo-
gies, including Fourier-domain OCT, have essen-
tially solved this problem by providing imaging at
rates 10- to 100-fold faster than first-generation
OCT. In combination with a short, nonocclusive
saline solution flush and rapid pullback, the faster
imaging speed of second-generation OCT technol-
ogy enables visualization of 3-dimensional micro-
structure of long coronary artery segments (30)
(Fig. 6). OCT can image important plaque charac-
teristics such as rupture, thrombus, thin caps, lipid
cores, and calcium. Recent technical advances in-
clude increased imaging frame rates (31), improved
resolution, and additional contrast mechanisms of-
fered by polarization (collagen) (32), Doppler flow
(33), and spectroscopic OCT (34). Multimodal
OCT technologies that incorporate molecular
probes (35) can provide combinations of structural
and molecular imaging. A major limitation of OCT
is its lack of penetration. As the external elastic
membrane of the entire coronary vessel cannot
usually be seen, it is typically not possible with
OCT to assess true vessel size and plaque burden.
Thus, all imaging modalities have inherent limita-
tions, and comparative natural history studies like the
PROSPECT study are required to determine their
relative accuracy in predicting future vulnerable
plaque-related events.
Intravascular magnetic resonance imaging: plaque
composition. Intravascular magnetic resonance imag-
ing (MRI), using pulse field gradient technology has
been used to calculate the water diffusion coefficient in
atherosclerotic plaques, thereby quantifying their lipid
contents using a conventional gray-scale image (36).
Preliminary data in human coronary arteries suggest
that intravascular MRI can accurately identify the
lipid, fibrous, and calcium content of plaque (37).
Limitations include the modest spatial resolution
(100 m) and the need to use an occluding balloon
o avoid signal interference from blood.
NoninvasiveCharacterizationof PlaqueMorphology
Computed tomography angiography: plaque attenua-
tion and PVR. Computed tomography angiography
CTA) has been predominantly investigated as a less
nvasive means to detect and quantify arterial lumen larrowing compared with traditional coronary an-
iography. In addition, CTA has a distinct advantage
f simultaneously demonstrating plaque and necrotic
ore extent and the type of segmental remodeling (38).
TA of disrupted plaques in patients who experi-
nced ACS (Fig. 7) showed PVR (external vessel wall
iameter of 110% compared with normal proximal
r distal segment) and low-attenuation plaque (LAP)
30 Hounsfield units) (39).
The 2 CTA features (PVR and LAP) in subjects
ho have not experienced ACS predict a higher
ikelihood of plaque rupture over time (39). In a
tudy of 10,000 coronary artery segments from
1,000 patients, individuals with 2-feature positive
laques demonstrated a 22% likelihood of the
evelopment of ACS over a 2-year follow-up period
ompared with 0.5% of those patients whose
laques showed neither PVR nor LAP (39). The
reater the remodeling and larger the plaque area,
he higher was the likelihood of patients experienc-
ng ACS and the earlier the acute event occurred.
he absence of these 2 features excluded the like-
Figure 5. NIRS Scan of a and Corresponding Coronary Angiogra
(Top) Cineangiographic frame of the right coronary artery of a 68-y
unstable angina. There is a severe, irregular culprit stenosis in the m
artery. (Bottom) Corresponding near-infrared spectroscopy (NIRS) c
prominent lipid core plaque (LCP) signal between 25 and 31 mm th
the culprit stenosis. There are 2 more proximal LCP signals between
that probably correspond to a single plaque mass in an angiograph
ment of the vessel. The block chemogram, which provides a summ
shows the strongest LCP signals between 26 to 31 mm, 45 to 47 m
Adapted, with permission, from Waxman et al. (27).m
ear-old man with
id-portion of the
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948patients. Patients with no coronary plaques did not
experience ACS on follow-up. Positively remodeled
lipid-rich plaques may demonstrate delayed con-
trast enhancement on serial imaging, suggesting the
presence of plaque neovascularization (40). Such
plaques are also predictive of slow or no-flow
outcomes after coronary intervention (41). Interven-
tions with statins cause parallel reductions in overall
plaque and LAP volumes and negative plaque remod-
eling, without significantly influencing the luminal
volume (42). Of interest, spotty calcification has been
reported to be more commonly associated with culprit
lesions, and large calcific plates with stable plaques
(42). The detection of activated macrophages using a
nanoparticulate computed tomography (CT) contrast
agent may allow insights into the biological activity of
plaque (43).
The interpretation of such features on CTA,
Figure 6. Optical Frequency Domain Imaging of the Left
Anterior Descending Coronary Artery, Obtained In Vivo
(A) Fly-through view (proximal-distal) demonstrates a yellow,
elevated lesion with scattered macrophages. (B) Optical fre-
quency domain cross-sectional imaging obtained at the location
of the white arrowhead in (A) shows a necrotic lipid core (L). A
thin cap is present (black arrow) with a dense band of macro-
phages at the cap–lipid pool interface. A thin ﬂap of tissue
(black arrowhead) can be seen over the cap. Adapted, with per-
mission, from Tearney et al. (30). (C) Fly-through view (proximal-
distal), demonstrates a calciﬁed lesion underneath a stent. (D)
Optical frequency domain cross-sectional imaging obtained at
the location of the black arrow in (C) shows a large calciﬁc nod-
ule (Ca) underneath the stent, from 11 to 5 o’clock. (A and C)
Artery wall in red, macrophages in green, lipid pool in yellow,
stent in blue. Tick marks, 1 mm. Asterisks denote guidewire
artifact.however, is not without limitations. Suboptimalresolution does not allow precise definition of the
vascular boundary, and the extent of PVR may be
overestimated or underestimated. Similarly, LAP is
defined based on the assessment of Hounsfield
units, and various imaging or technical parameters
may significantly influence the soft plaque measure-
ments. The comparison of IVUS and CTA has
demonstrated that the majority of echolucent
plaque cores measured 30 Hounsfield units (38).
eavy plaque calcification in some patients may
reclude obtaining information about plaque vul-
erability. Also, plaque erosions are currently not
menable to CT characterization. CTA is not indi-
ated in the evaluation of most asymptomatic patients
iven the fear of radiation burden. Primary prevention
tudies are needed to evaluate the merit of plaque
haracterization and to define the population that will
enefit the most from such a strategy.
Figure 7. Morphological Characteristics on Coronary CTA
of an Atherosclerotic Lesion Resulting in ACS
(Top) Curved multiplanar reformation image of the left anterior
descending artery (LAD) shows positive remodeling, low-attenu-
ation plaque, and spotty calciﬁcation at site 6 on computed
tomography angiography (CTA). (Bottom) Acute coronary syn-
drome (ACS) occurred 6 months after CTA. LAD site 6 was the
culprit lesion based on invasive coronary angiography. The elec-
trocardiograms at initial presentation and during the subse-
quent event are shown. Reprinted, with permission, from
Motoyama et al. (39).
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949MRI: plaque morphology and intraplaque hemorrhage.
The superficial location and relative immobility of
the carotid artery provide optimal conditions for
serial in vivo imaging of human atherosclerosis.
Histological studies have shown that many features
described in high-risk coronary atherosclerosis are
also observed in carotid plaques excised from pa-
tients with recent ischemic stroke (44). Patients
undergoing carotid endarterectomy provide the
unique opportunity to validate in vivo pre-operative
imaging of human atherosclerosis by detailed his-
tological analysis of intact excised specimens. MRI
can accurately characterize key features of carotid
atherosclerosis, including the fibrous cap (45), ne-
crotic core (45), intraplaque hemorrhage (IPH),
and mural thrombus (46) (Fig. 8). The rate of
diffusion of gadolinium contrast into the carotid
vessel wall via dynamic contrast-enhanced MRI
allows assessment of plaque macrophage content
and degree of plaque neovascularization (47).
A prospective, longitudinal MRI study in 154
asymptomatic patients with 50% to 80% carotid
stenosis demonstrated that a thin or ruptured fi-
Figure 8. Morphological Characteristics of Carotid Artery Ather
3-T magnetic resonance imaging (MRI) of a plaque in the right com
mation (yellow arrows). The crescent-shaped high-signal region in
enhanced T1-weighted (CE-T1W) images correspond to a region of
(hematoxylin and eosin stain). TOF  time of ﬂight. Adapted, with
carotid atherosclerotic plaque ulceration, calciﬁcation, and thrombo
tion 2005;112:e3–4.brous cap (HR: 17.0; p  0.001), IPH (HR: 5.2;
 0.005), and larger mean necrotic core area
HR: 1.6; p  0.01 per 10-mm2 increment) were
plaque features predictive of subsequent transient
ischemic attack or stroke during a mean follow-up
of 3 years (48). Another study of 64 recently
symptomatic patients with 30% to 70% carotid
stenosis confirmed the critical role of IPH in the
development of subsequent transient ischemic at-
tack or stroke (49). IPH was observed in 60% of the
ipsilateral carotid arteries on baseline MRI. During
a median follow-up of 28 months, 14 ipsilateral
ischemic events occurred, 13 of which occurred in
carotid arteries with IPH (HR: 9.8; p  0.03).
These single-center, prospective studies provide
compelling preliminary evidence that specific MRI-
identified carotid plaque features are associated with
an increased risk of future ischemic events. Larger
multicenter studies are needed to confirm these
promising initial findings and to determine the
plaque features most predictive of future events.
Arteriosclerotic plaque burden in the abdominal
aorta can be measured using multicontrast-
erosis Using MRI
n carotid artery demonstrates ﬁbrous cap rupture with ulcer for-
proton density-weighted (PDW), T2-weighted (T2W), and contrast-
mbus formation, shown on the matched histology section
ission, from Chu B, Ferguson MS, Underhill H, et al. Detection of
y multicontrast weighted magnetic resonance imaging. Circula-oscl
mo
the
thro
perm
sis b
artery dise
oxide.
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950weighted MRI (50). Studies have demonstrated
regression of abdominal aortic plaque burden after
intensive statin therapy (51).
Positron emission tomography and molecular imaging:
plaque inﬂammation. Quantifying plaque inflam-
mation may be valuable for several reasons. Patho-
logical studies in patients dying after an ACS event
have demonstrated intense inflammation in the
culprit plaques, and epidemiological studies have
confirmed the association between biomarkers of
systemic inflammation and the development of
acute coronary events.
Noninvasive quantification of inflammation by
molecular imaging has most commonly used single-
photon emission CT and positron emission tomog-
raphy (PET) (52–55). The superior spatial resolu-
tion of PET (4 to 5 mm) makes it more attractive
than single-photon emission CT (10 to 15 mm).
Imaging Arterial Inﬂammation Using FDG-PET
demonstrating enhanced aortic uptake of ﬂuorodeoxyglucose (FDG)
n emission tomography (PET) scan, indicating inﬂammation in the
ll due to atherosclerosis. (B) Co-registered FDG-PET/computed tomog-
es showing FDG uptake at the left main coronary artery trifurcation
w) in a patient with acute coronary syndrome. Aortic FDG uptake is
y the dashed arrow. In such patients, both aortic and coronary
uptake was increased compared with patients with stable coronary
of Noninvasive Assessment of Atherosclerotic Plaques in Human
MRI and
Multicontrast MR DCE (Gd)-MRI USPIO MRI
F
o
Carotid, aorta, peripheral Carotid, aorta,
peripheral
Carotid, aorta,
peripheral
C
Burden, remodeling,
lipid-rich necrotic core
Inﬂammation,
neovascularization
Inﬂammation In
5%–10% 15% N/A
3, 6, 12, 18 N/A 3
0.5 0.5 0.5
e point.
aphy; DCE (Gd)  dynamic contrast-enhanced gadolinium; FDG  ﬂuorodeoxyg
positron emission tomography; SPECT  single-photon emission computed tomase. Image courtesy of Dr. Zahi A. Fayad.Further, PET modalities demonstrate sensitivity for
the detection of molecular targets within the pico-
molar range, translating into the ability to use small
doses of contrast agent compared with MRI and
CT. However, the spatial and temporal resolution of
MRI and CT are superior to nuclear imaging tech-
niques, and hybrid imaging combining CT or MRI
with PET or single-photon emission CT provides the
best avenues for molecular imaging. Imaging tech-
niques such as fluorodeoxyglucose (FDG) PET (53),
dynamic contrast enhancement MRI (54), and ultra-
small particle iron oxide–enhanced MRI (55) are close
to clinical applicability (Table 1). A strong direct
correlation between carotid FDG uptake and macro-
phage density (mean percentage of staining of
CD68 cells) in the carotid endarterectomy speci-
mens has been demonstrated (56), supporting the
hypothesis that glucose uptake in atherosclerotic
plaques parallels inflammatory activity. FDG uptake
did not correlate with plaque area, thickness, or
smooth muscle cell prevalence. Serial prospective
FDG uptake studies have reported excellent interob-
server, intraobserver, and interscan reproducibility.
After anecdotal reports of FDG uptake in coro-
nary arteries (57), a recent prospective FDG PET-
CTA study demonstrated the feasibility of FDG
localization in inflamed coronary arteries (Fig. 9)
(58). In patients who had undergone coronary stent
implantation for ACS or chronic stable angina,
culprit lesions demonstrated substantially higher
FDG uptake compared with stable target lesions.
FDG uptake was also prominently present in some
nonstented coronary segments, particularly at the
left main bifurcation and also in the aortic root (58).
Although this study suggests the possibility of
PET With
ithout CT SPECT MDCT
id, aorta,
ripheral,
ronary
Carotid, peripheral Carotid, aorta, peripheral,
coronary
mation
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annexin A5)
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%–7% N/A 20%
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951will be necessary to reduce the radiation exposure
from combined PET/CT studies. Newer PET trac-
ers that offer promise in detecting increased biolog-
ical plaque activity include 11C-PK11195 and 18F-
FEDAA (59), (macrophage infiltration), and 68Ga-
DOTATATE (somatostatin receptor analog) (60).
Ultrasound imaging: carotid plaque morphology and
neovascularization. B-mode ultrasound with pulse-
wave and color Doppler is a convenient noninvasive
means to determine the presence and size of plaques
in superficial arteries such as the carotid. Plaque can
be characterized as homogeneous or heterogeneous.
The latter are more likely to be unstable, with a
higher potential for embolization or thrombosis
(61). Such plaques generally have low calcium
content but large amounts of intraplaque hemor-
rhage and lipid, which make them appear hy-
poechoic (62). In contrast, calcified (hard) plaque is
generally stable and has high echogenicity. Ulcer-
ated plaque may demonstrate eddy flow within the
plaque depressions on Doppler or gray-scale flow
imaging (63).
Intravenous injection of a contrast agent allows
detection of plaque neovascularization, a frequent
forerunner of IPH, thus providing additional infor-
mation to that from standard ultrasound imaging
(64). Transesophageal echocardiography has been
used to identify ulcerated plaque in the aortic arch
and proximal descending aorta, which is associated
with increased risk of ischemic stroke (65).
Screening Before Imaging Procedures:
Protein and Genetic Biomarkers
Although the development of imaging techniques
will remain the cornerstone for the recognition of
vulnerable plaques, it is equally important to define
a strategy for identifying individuals who will benefit
most from these imaging procedures. Circulating
biomarkers of inflammation and genetic assessment
appear especially promising to identify high-risk
patients for potential noninvasive and possibly in-
vasive imaging.
The most widely tested of the inflammatory
biomarkers is high-sensitivity C-reactive protein,
which has been shown to predict the risk of a first
MI in healthy cohorts and future coronary events in
patients with stable CAD (66). Whether C-reactive
protein is directly causal remains contested, but the
association with clinical events remains clear. Mul-
tiple other circulating markers hold promise but
have not been as widely tested. These include
lipoprotein-associated phospholipase A2 (67), se-cretory type II phospholipase A2 (68), oxidized
ow-density lipoprotein (69), myeloperoxidase (70),
nd pregnancy-associated plasma protein A (71). In
ddition to plaque-related circulating markers, sev-
ral common genetic variants have been reproduc-
bly associated with CAD risk. Each copy of the
isk allele at 9p21 increases CAD risk by 25%, and
50% of individuals of European ancestry harbor at
east 1 copy of the risk allele (72). Recently, a
ultistage genome-wide association study identi-
ed 9 genetic variants associated with early-onset
I: 3 of these are newly identified (21q22, 6p24,
nd 2q33) and 6 (9p21, 1p13, 10q11, 1q41, 19p13,
nd 1p32) replicated previous observations. To
valuate the cumulative effect of these single-
ucleotide polymorphisms on the risk of MI, a
enotype score from 9 single-nucleotide polymor-
hisms was created. Individuals with scores in the
op quintile had a 2-fold increase in risk of MI
ompared with those in the bottom quintile (73).
An important potential use of biomarkers is to
uide the use of noninvasive and/or invasive imaging
rocedures. In 1,004 asymptomatic Korean patients
ho underwent coronary CTA imaging as part of a
ealth screening, individuals with C-reactive protein
2 mg/l had a much higher prevalence of coronary
laque (30.7% vs. 16.7%) and mixed calcific plaque
19.3% vs. 6.3%) compared with those with lower
-reactive protein levels (74).
Animal Models of Unstable Atherosclerotic Plaques
Several animal models of atherosclerosis have been
developed for vulnerable plaque research over the
past 50 years. The selection of the most appropriate
model depends on whether plaque morphology,
rupture, or thrombosis is the main objective of the
proposed research. Atherosclerotic lesions, most
similar to those in humans, develop in the rhesus
monkey (75). Although appealing due to their
genetic background and biological similarities to
humans, primates have not been widely used be-
cause of ethical issues, risk to experimenters, and
maintenance costs.
Swine models of atherosclerosis are particularly
relevant due to their close anatomic and biological
resemblance to the human coronary vasculature
(76). The familial hypercholesterolemic swine has
severe hypercholesterolemia (350 mg/dl) even if
maintained on a cholesterol-free diet and complex
atheromatous lesions develop in 18 months. Eccen-
tric lesions resembling human-like TCFAs develop
in this strain of animal. More advanced lesions
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952including large necrotic cores, thinning of the
fibrous cap, and IPH are commonly seen in pigs
older than 2 years. Similarly, streptozotocin-
induced diabetes in swine produces an accelerated
form of atherosclerosis, especially when combined
with a high cholesterol diet. Atheromatous lesions
in this model develop in the first 2 to 3 cm of the
proximal arteries as early as 20 weeks after the
induction of diabetes. In addition, their well-
described genetic background, as well as their vas-
cular response to therapies, makes these models
suitable for research in which a well-defined coro-
nary territory is required. The atherosclerotic rabbit
is a cost-effective model of atherosclerosis if the
coronary territory is not a specific target of the
proposed research. Although the morphology of the
lesions differs from late-stage human atherosclero-
sis, macrophage foam cell–rich atherosclerotic
plaques develop relatively rapidly in cholesterol-fed
rabbits (77). The development period of these lesions
can be shortened by inducing initial endothelial injury
or by intramural injection of proatherosclerotic mate-
rial such as red blood cell membranes.
Previously healed ruptures are commonly found in
porcine atherosclerotic models and less commonly in
rabbits. In small animal models, particularly geneti-
cally manipulated mice, complex atheromas usually
develop after cholesterol diet supplementation and
frequently atypically ruptured lesions in the innomi-
nate artery develop. In such models, a combination of
dietary manipulation and the application of mechan-
ical obstructions such as cuffs have shortened the
development time and increased the reproducibility,
Table 2. Features of Different Animal Models of Atherosclerosis
Therapeutic Technologies
Mice
Pathology of atherosclerosis similar to humans
Prominent necrotic core
Positive vascular remodeling
Thinned ﬁbrous cap
Evidence of plaque rupture
Known genetic background
Simple development method
Metabolic proﬁle similar to humans
Short development time (6 months)
Ability to perform noninvasive imaging
Ability to perform invasive imaging
Ability to perform systemic therapeutic interventions
Ability to perform invasive therapeutic procedures
Development cost
*Usually evident as intraplaque hemorrhage. †The Watanabe rabbit and the FH
triglyceride levels. §Lesions develop in the diabetic swine between 5 and 9 monthscomplexity, and likelihood of rupture of the induced
lesions (78).
Innovative imaging detection and therapeutic
technologies will ultimately depend on developing
successful animal models and standardizing lesion
definitions, permitting preclinical validation of the
technology in a controlled environment. The morpho-
logical features and clinical utility of various animal
models of atherosclerosis are shown in Table 2.
Broad Recommendations From theWorking Group
1. Identifying vulnerable plaques and deﬁning their
natural history. For noninvasive imaging techniques
to find clinical application, they must identify high-
risk subjects with several-fold better predictive value
than currently available clinical approaches. Invasive
techniques will need at least 2-fold better predictive
power than noninvasive techniques for clinical util-
ity. PROSPECT-type studies are necessary to
demonstrate that high-risk lesions identified by
either noninvasive or invasive imaging are the focal
cause of future MACE (i.e., due to plaque rupture
and/or thrombosis) and/or correlate with imaging
tools previously validated to predict clinical events
(which at present has only been proven for
RF-IVUS).
2. Developing effective preventive strategies. After
vulnerable plaques (and vulnerable patients) are
identified, pharmaceutical and/or device-based in-
terventional tools are needed that may delay or
obviate an ominous course for these high-risk
plaques and patients.
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9533. Determining cost-effectiveness of diagnostic and
therapeutic approaches. Cost-effectiveness studies
re mandatory to define the optimal populations
nd strategies for noninvasive screening, invasive
maging, and potential management of high-risk
laques and patients. It is likely that a combination
f selected risk factors, biomarkers, and noninvasive
maging in high-risk populations will best deter-
ine who should undergo invasive imaging.
Recommendations for Future Research
1. Improve understanding of the plaque microenviron-
ment in the pathogenesis of plaque instability. Ex-
amples of possible research proposals include in-
flammation and immune cell responses, the role of
neovascularization and intraplaque hemorrhage,
and the role of extracellular matrix composition and
biomechanical stress.
2. Develop and validate molecular and genetic markers
of vulnerable plaque. Examples of possible research
roposals include the use of biomarkers to elucidate
athological processes underlying stable and unsta-
le plaques; the use of biomarkers and blood coag-tion. Circulation 2005;111:143–9.
1
1
plaques. Circulationression, rupture, or erosion; and the use of
iomarkers to assess response to intervention.
3. Develop and validate noninvasive and invasive
imaging techniques to identify, monitor, and treat
vulnerable plaques. Examples of possible research
proposals include animal studies to validate prom-
ising imaging techniques and molecular markers,
with histology both before and after intervention;
standardization of acquisition and interpretation of
promising imaging techniques; small natural history
studies and response to pharmacological or
catheter-based interventions in humans using
single- or dual-imaging techniques; and large nat-
ural history studies and phase 2 treatment trials
evaluating the response to pharmacological or
catheter-based interventions in humans using
single- or multiple-imaging techniques. When pos-
sible, such investigations should be leveraged to
existing studies to maximize cost-effectiveness.
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